Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 30 Jun 2025 OSAKA, Japan & CAMBRIDGE, Mass.

After turning down Takeda's Fruzaqla for metastatic colorectal cancer (mCRC) in draft guidance last year, NICE has changed its mind and recommended the drug for use by the NHS in England and Wales.